RESUMO
BACKGROUND: This study aimed to investigate the effect of vildagliptin-containing polyelectrolyte complex microbeads formulation in a streptozotocin-induced diabetic rat model. OBJECTIVE: Vildagliptin-containing polyelectrolyte complex microbeads were given to diabetic rats at a dose of 2.5 mg/kg body weight in order to study their antidiabetic, hypolipidemic histopathological conditions. METHODS: A portable glucometer was used to measure the blood glucose level using a reagent strip. After vildagliptin formulation was administered orally to healthy streptozotocin-induced rats, other parameters, such as liver profile and total lipid levels, were assessed. RESULT: Vildagliptin-containing polyelectrolyte complex microbeads were found to significantly decrease high glucose levels and improve kidney, liver, and hyperlipidaemia caused due to diabetes. Vildagliptin-containing polyelectrolyte complex microbeads also had a favourable impact on alterations in the liver and pancreatic histopathology in diabetes caused by streptozotocin. CONCLUSION: Vildagliptin-containing polyelectrolyte complex microbeads have the ability to enhance a variety of lipid profiles, including those related to body weight, liver, kidney, and total lipid profiles. Vildagliptin-containing polyelectrolyte complex microbeads have also been found to be effective in preventing the histological alterations in the liver and pancreas occurred in streptozotocin-induced diabetes.
